Prevalence and clinicopathological characteristics of islet amyloid in chinese patients with type 2 diabetes

被引:96
|
作者
Zhao, HL [1 ]
Lai, FMM
Tong, PCY
Zhong, DR
Yang, D
Tomlinson, B
Chan, JCN
机构
[1] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut, Shatin, Hong Kong, Peoples R China
[2] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Anat & Cellular Pathol, Shatin, Hong Kong, Peoples R China
[3] Chinese Peoples Liberat Army Gen Hosp, Dept Pathol, Beijing, Peoples R China
[4] Peking Union Coll Hosp, Dept Pathol, Beijing, Peoples R China
关键词
D O I
10.2337/diabetes.52.11.2759
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Islet amyloid has been suggested to be an important link between insulin resistance and R-cell dysfunction in type 2 diabetes. To investigate the prevalence and clinicopathological characteristics of islet amyloid, we examined consecutive autopsies of 235 Chinese patients with type 2 diabetes and 533 nondiabetic subjects. Islet amyloid deposits were identified using Congo red staining and quantitated by image analysis. We found that 3.0% of the nondiabetic subjects versus 39.6% of the diabetic patients displayed islet amyloid (P < 0.001). In diabetic patients, the amyloid deposits occupied a mean islet area of 36.2%, which was positively associated with BMI, blood pressure, and glycemic control. Pancreatic fibrosis and fat infiltration were more frequently found in diabetic patients with islet amyloid than those without islet amyloid, whereas pancreatic arteriosclerosis was identified in all diabetic patients. These findings suggest that islet amyloid deposits reflect greater insulin resistance and islet failure in a subgroup of type 2 diabetic patients. Islet failure may also have been exacerbated by fat infiltration, fibrosis, and arteriosclerosis. Optimal blood pressure and metabolic control may reduce these pathological changes and help preserve islet cell mass.
引用
收藏
页码:2759 / 2766
页数:8
相关论文
共 50 条
  • [1] Clinicopathological characteristics of islet amyloid in Type 2 diabetes mellitus.
    Zhao, H
    Lai, FMM
    Tong, PCY
    Tomlinson, B
    Chan, JCN
    DIABETOLOGIA, 2003, 46 : A157 - A157
  • [2] Low prevalence of islet amyloidosis in Chinese patients with type 2 diabetes
    Zhao, HL
    Lee, SC
    Lai, FM
    Yin, H
    Yang, D
    Thomas, GN
    Critchley, JAJH
    Cockram, CS
    Chan, JC
    DIABETES, 2001, 50 : A313 - A313
  • [3] Islet amyloid and type 2 diabetes mellitus
    Höppener, JWM
    Ahrén, B
    Lips, CJM
    NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (06): : 411 - 419
  • [4] ISLET AMYLOID AND TYPE-2 DIABETES
    CLARK, A
    DIABETIC MEDICINE, 1989, 6 (07) : 561 - 567
  • [5] The implication for islet amyloid in type 2 diabetes
    Westermark, G. T.
    FEBS JOURNAL, 2008, 275 : 27 - 27
  • [6] Islet amyloid polypeptide and type 2 diabetes
    Marzban, L
    Park, K
    Verchere, CB
    EXPERIMENTAL GERONTOLOGY, 2003, 38 (04) : 347 - 351
  • [7] The Prevalence of Sarcopenia in Chinese Type 2 Diabetes Patients
    He, Qinghua
    Guo, Lixin
    DIABETES, 2020, 69
  • [8] Role of islet amyloid in type 2 diabetes mellitus
    Höppener, JWM
    Lips, CJM
    INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2006, 38 (5-6): : 726 - 736
  • [9] ISLET AMYLOID - AN ENIGMA OF TYPE-2 DIABETES
    CLARK, A
    DIABETES-METABOLISM REVIEWS, 1992, 8 (02): : 117 - 132
  • [10] Islet Amyloid in Patients With Diabetes Due to Exocrine Pancreatic Disorders, Type 2 Diabetes, and Nondiabetic Patients
    Ueberberg, Sandra
    Nauck, Michael A.
    Uhl, Waldemar
    Montemurro, Chiara
    Tannapfel, Andrea
    Clark, Anne
    Meier, Juris J.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2020, 105 (08): : 2595 - 2605